Although capable of resulting in end-organ damage, it is not entirely clear to what extent circulating cytokines contribute to the pathogenesis of CoV-AKI, bearing in mind that circulating levels of cytokines like interleukin-6 (IL-6) are considerably lower in patients with COVID-19 when compared to those seen after CAR T-cell therapy or sepsis. The gene discussed is IL6; the disease is COVID-19.